Skip to content

Study · Non-randomized trial · n = 9 · 1996

2 results

Reduced intravenous glutathione in the treatment of early Parkinson's disease.

Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G

Progress in neuro-psychopharmacology & biological psychiatry1 Oct 1996Cited by 109 (Europe PMC)

PMID8938817 (opens in a new tab)DOI10.1016/s0278-5846(96)00103-0 (opens in a new tab)PepBankPUB-08938817
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with early untreated Parkinson's disease, glutathione therapy reduced disability by 42% from baseline.

    In plain wordsIn patients with early untreated Parkinson's disease, glutathione reduced disability by 42% from baseline.

    Peptide
    Glutathione
    Outcome
    DecreaseClinical disability
    Study

    n = 9

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    600 mg twice daily · intravenous · 30 daysAs given in this study (human).

    Measurements

    Decline in clinical disability
    42%
    After GSH therapy versus baseline

    Source sentences

    Summary
    All patients improved significantly after GSH therapy, with a 42% decline in disability.
    2 context sentences
    Summary · context
    The authors studied the effects of GSH in nine patients with early, untreated PD.
    Summary · context
    GSH was administered intravenous, 600 mg twice daily, for 30 days, in an open label fashion.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with early untreated Parkinson's disease, the glutathione therapeutic effect lasted for 2-4 months after treatment stopped.

    In plain wordsIn patients with early untreated Parkinson's disease, the glutathione treatment effect lasted for 2-4 months after treatment stopped.

    Peptide
    Glutathione
    Outcome
    Not applicablePersistence of therapeutic effect
    Study

    n = 9

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    600 mg twice daily · intravenous · 30 daysAs given in this study (human).

    Measurements

    Persistence of therapeutic effect
    2 to 4 months
    After GSH stopped

    Source sentences

    Summary
    Once GSH was stopped the therapeutic effect lasted for 2-4 months.
    2 context sentences
    Summary · context
    The authors studied the effects of GSH in nine patients with early, untreated PD.
    Summary · context
    GSH was administered intravenous, 600 mg twice daily, for 30 days, in an open label fashion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02424708

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

Bastyr Universityn = 45Apr 2015 to Apr 2016

Parkinson's Disease

Trial pageClinicalTrials.govUpdated 24 Jun 2016
CompletedPhase 1NCT02324426

CNS Uptake of Intranasal Glutathione

University of Washingtonn = 15Dec 2014 to Mar 2015

Parkinson's Disease

Trial pageClinicalTrials.govUpdated 30 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.